Our observation also revealed, on average, more than 2% of CD4+ lymphocytes in TDLNs of patients with BC produced IL-22; however, the majority of them simultaneously expressed IFN-γ and to a lesser extent, IL-17. This evidence concerns the gene IL17A and breast cancer.